News Conference News ESC Heart Failure 2022 HF Triple Therapy Doesn’t Seem Effective in True Preserved HF Shelley Wood May 25, 2022
News Conference News ESC Heart Failure 2022 Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients Shelley Wood May 23, 2022
News Conference News ESC Heart Failure 2022 Dapagliflozin Boosts Health Status Across LVEF Range Shelley Wood May 23, 2022
News Conference News ESC Heart Failure 2022 Speech-Recognition Tool May Predict Worsening Congestion in HF Shelley Wood May 22, 2022
News Daily News ESC Heart Failure 2022 SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH Shelley Wood May 22, 2022
News Conference News EuroPCR 2022 MitraClip Helps for Atrial Functional MR: MITRA-TUNE Michael O'Riordan May 19, 2022
News Daily News The Hunt for Protein Culprits in COVID-19’s Cardiac Complications Michael O'Riordan May 06, 2022
News Daily News FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy Michael O'Riordan April 29, 2022
News Daily News CVD Hospitalizations Spiked in Aftermath of 2020 US Election Michael O'Riordan April 22, 2022
News Conference News ACC 2022 DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF L.A. McKeown April 08, 2022
News Conference News ACC 2022 METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF Todd Neale April 08, 2022
News Conference News ACC 2022 QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis L.A. McKeown April 07, 2022
Presentation ACC 2022 A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF Presenter: Tariq Ahmad April 04, 2022
News Conference News ACC 2022 PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization L.A. McKeown April 03, 2022
News Conference News ACC 2022 Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term Shelley Wood April 03, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Daily News Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia L.A. McKeown March 22, 2022
News Daily News Guideline-Directed Therapies Underused in Frail HF Patients L.A. McKeown March 11, 2022
News Daily News FDA Approves Empagliflozin for Treatment of HFpEF Michael O'Riordan February 24, 2022